Binding proteins to the human thrombin receptor, par4

A technology combining protein and thrombin, applied in the direction of anti-animal/human immunoglobulin, anti-receptor/cell surface antigen/cell surface determinant immunoglobulin, immunoglobulin, etc., can solve the unsatisfactory treatment of thrombosis. Medical needs, etc.

Pending Publication Date: 2020-09-15
MONASH UNIV
View PDF77 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Furthermore, thrombosis therapy with minimal adverse side effects is a significant unmet medical need

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Binding proteins to the human thrombin receptor, par4
  • Binding proteins to the human thrombin receptor, par4
  • Binding proteins to the human thrombin receptor, par4

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0833] Example 1 Development of antagonist monoclonal antibody against human PAR4

[0834] The inventors tried to develop a monoclonal antibody targeting human PAR4. Antibody production and screening are performed at Monash Antibody Technology Facility (MATF) by its director Professor Mark Sleeman using Regeneron Pharmaceuticals' proprietary HumAb mice This was done to generate high-affinity antibodies against PAR4, as described in further detail below.

[0835] (i) Immunization

[0836] The KLH-conjugated peptide at the N-terminal thrombin cleavage and activation site of human PAR4 (hPAR4) was generated and used to immunize HumAb mice, followed by three booster immunizations according to the standard protocol. Serum titer was determined by ELISA using naked hPAR4 peptide (Table 3).

[0837] A total of 12 HumAb mice were subjected to three independent immunization programs using the peptide. The sequence of the peptide used for immunization is shown in Table 3, and in some cases ...

Embodiment 2

[0862] Example 2 Anti-PAR4 hybridoma clone blocks thrombin-induced PAR4 cleavage

[0863] The ability of monoclonal antibody hybridoma supernatants (MoB5ARC3, MoB5BRB4, MoB5BRC6, MoB5BRH3 and MoB5CRC4) to cleave intact PAR4 present on the surface of HEK293 cells transfected with human PAR4 containing N-terminal FLAG tag was screened. By flow cytometry and as figure 2 Quantitative cutting shown.

[0864] Combine the transfected HEK293 cells with any anti-PAR4 polyclonal antibody (described in French SL et al. (2016) JThromb Haemost 14, 1642-1654, used as a positive control) or monoclonal antibody clones MoB5ARC3, MoB5BRB4, MoB5BRC6, MoB5BRH3 Or MoB5CRC4 and an untreated negative control are incubated for 10 minutes in the presence of thrombin (0.1U / ml) at room temperature. The cleavage of PAR4 by thrombin was measured by the loss of FLAG tags from PAR4-expressing HEK293T cells using flow cytometry.

[0865] Treatment of cells with thrombin (2U / ml for 10 minutes) resulted in approx...

Embodiment 3

[0869] Example 3 Binding specificity of H4b and B6b subclones of mAb-5RC3

[0870] To determine the specificity of anti-hPAR4 clones for PAR4, ELISA screening was performed as described above. Figure 5 A shows the results of the binding specificity of clones mAb-5ARC3 (5A.RC3) and mAb-5BRB4 (5B.RB4) for hPAR1, hPAR2, hPAR3 and hPAR4.

[0871] 5A. RC3 shows 16-fold selectivity to human PAR4 peptide over PAR1, PAR2 and PAR3. Compared with 5A.RC3, mAb5B.RB4 similarly binds to all four human PAR peptides and has a lower affinity for PAR4.

[0872] The inventors used Bio-Rad Proteon XPR36 to perform surface plasmon resonance (SPR) analysis to gain insight into the binding affinity (association and dissociation rate) and specificity of 5A.RC3.F10b.H4b. Using the streptavidin chip, all biotin-conjugated human PAR peptides (Table 1) were captured on the surface, and different concentrations of purified 5A.RC3 passed. It was observed by SA chip SPR that clone 5A.RC3.F10b.H4b has a dissoci...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present disclosure is directed to human protease activated receptor 4 (PAR4) binding proteins (e.g. antibodies). In particular, anti-PAR4 binding proteins which are antagonists of human PAR4, as well as methods and uses thereof.

Description

[0001] [Incorporated by reference] [0002] All documents cited or referenced herein and all documents cited or referenced in the documents cited herein, as well as any manufacturer's instructions, descriptions, and descriptions in any products mentioned herein or any documents incorporated by reference in this document The product specification and product list are hereby incorporated by reference in their entirety. [0003] This application claims the priority of Australian patent application 2017903685 filed on September 11, 2017, the entire content of which is incorporated herein by reference. [0004] The entire content of the electronic submission of the sequence listing is incorporated by reference in its entirety for all purposes. 【Technical Field】 [0005] The present disclosure relates to human protease activated receptor 4 (PAR4) binding proteins (eg antibodies). In particular, an anti-PAR4 binding protein as an antagonist of human PAR4 and its method and use. [0006] [Bac...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28A61K39/395A61P7/02
CPCC07K16/28A61K2039/505C07K2317/76C07K2317/34A61P7/02A61K39/3955C07K2317/56C07K2317/92A61K47/6849C07K2317/524C07K2317/526C07K2317/565C07K2317/622
Inventor J·哈米尔顿M·斯利曼
Owner MONASH UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap